Clinical trial · Interventional
Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase I/II Randomized Trial Comparing Two Treatment Schedules Of Gemcitabine In Poor Prognosis Status Patients With Advanced Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Treatment plus supportive care may improve quality of life in patients undergoing cancer treatment. PURPOSE: Randomized phase II/III trial to compare the effect of different gemcitabine regimens plus supportive care on quality of life in patients who have locally advanced or metastatic non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gemcitabine hydrochloride | Drug | Gemcitabine | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically proven locally advanced or metastatic non-small cell lung cancer that is not amenable to curative surgery or radiotherapy * No known CNS metastases * No concurrent cord compression or superior vena cava syndrome requiring immediate radiotherapy PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 40-70% Life expectancy: * At least 4 weeks Hematopoietic: * WBC at least 3,500/mm3 * Platelet count at least 100,000/mm3 * Hemoglobin at least 10.0 g/dL Hepatic: * Bilirubin no greater than 3 times normal * ALT and AST no greater than 3 times normal (5 times normal if liver metastasis present) Renal: * Creatinine no greater than 1.5 times normal Other: * Not pregnant or nursing * Fertile patients must use effective contraception during and for at least 3 months after study * No active infection * No other concurrent serious, systemic disorder that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy * No other concurrent systemic chemotherapy Endocrine therapy: * Concurrent steroids allowed Radiotherapy: * See Disease Characteristics * Concurrent palliative radiotherapy allowed * No concurrent curative radiotherapy Surgery: * See Disease Characteristics * Concurrent palliative surgery allowed
References
Publications (0)
Data not yet available